Guardant Health CIO sells 3,418 shares at $130

Guardant Health, Inc. Chief Information Officer Kumud Kalia reported an open-market sale of 3,418 shares of Common Stock on June 11, 2026 at an average price of $130.2386 per share.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Guardant Health, Inc. Chief Information Officer Kumud Kalia reported an open-market sale of 3,418 shares of Common Stock on June 11, 2026 at an average price of $130.2386 per share. After this transaction, Kalia directly holds 41,090 shares, indicating he retains a substantial ongoing equity stake.

Insider Trade Summary

Net Seller: 3,418 shares

Net Sell 1 txn

Insider Kalia Kumud

Role Chief Information Officer

Sold 3,418 shs ($445K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,418	$130.2386	$445K

Holdings After Transaction: Common Stock — 41,090 shares (Direct)

Key Figures

Shares sold: 3,418 shares Sale price per share: $130.2386 per share Shares held after transaction: 41,090 shares +2 more

5 metrics

Shares sold 3,418 shares Open-market sale of Common Stock on June 11, 2026

Sale price per share $130.2386 per share Average price for the June 11, 2026 sale

Shares held after transaction 41,090 shares Direct ownership by Kumud Kalia following the sale

Transaction type Open-market sale Form 4 code S, non-derivative Common Stock

Net buy/sell direction Net sell of 3,418 shares transactionSummary netBuySellShares

Key Terms

open-market sale, Common Stock, Form 4, non-derivative

4 terms

open-market sale financial

"classified as an open-market sale of Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"open-market sale of 3,418 shares of Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"The transaction was reported on Form 4 and reflects routine"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

"This was classified as an open-market sale transaction in the Form 4 insider trading report and involved non-derivative Common Stock."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Guardant Health (GH) disclose for Kumud Kalia?

Guardant Health disclosed that Chief Information Officer Kumud Kalia executed an open-market sale of 3,418 shares of Common Stock. The transaction was reported on Form 4 and reflects routine insider trading activity by a senior executive.

How many Guardant Health (GH) shares did Kumud Kalia sell and at what price?

Kumud Kalia sold 3,418 shares of Guardant Health Common Stock at an average price of $130.2386 per share. This was classified as an open-market sale transaction in the Form 4 insider trading report.

How many Guardant Health (GH) shares does Kumud Kalia hold after the sale?

Following the reported sale, Kumud Kalia holds 41,090 shares of Guardant Health Common Stock directly. This post-transaction balance shows he continues to maintain a meaningful ownership position in the company after the June 11, 2026 trade.

Was the Guardant Health (GH) insider trade by Kumud Kalia a buy or sell?

The insider trade reported for Kumud Kalia was a sale transaction. The Form 4 classifies it as an open-market sale of Common Stock, reflecting a disposition rather than an acquisition of Guardant Health shares by the Chief Information Officer.

What type of security did Kumud Kalia trade in the Guardant Health (GH) Form 4?

The Form 4 shows that Kumud Kalia traded Guardant Health Common Stock, not options or other derivatives. There were no derivative securities reported in this filing, and the entire transaction involved non-derivative Common Stock shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/15/2026 - 06:09 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalia Kumud

(Last)

(First)

(Middle)

3100 HANOVER STREET

(Street)

PALO ALTO

CALIFORNIA

94304

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Information Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/11/2026		S		3,418	D	$130.2386	41,090	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Kumud Kalia	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR